NO20061396L - Nye heterocykliske forbindelser som HSP90-inhibitorer - Google Patents

Nye heterocykliske forbindelser som HSP90-inhibitorer

Info

Publication number
NO20061396L
NO20061396L NO20061396A NO20061396A NO20061396L NO 20061396 L NO20061396 L NO 20061396L NO 20061396 A NO20061396 A NO 20061396A NO 20061396 A NO20061396 A NO 20061396A NO 20061396 L NO20061396 L NO 20061396L
Authority
NO
Norway
Prior art keywords
heterocyclic compounds
new heterocyclic
hsp90 inhibitors
hsp90
inhibitors
Prior art date
Application number
NO20061396A
Other languages
English (en)
Norwegian (no)
Inventor
Srinivas Rao Kasibhatla
Lin Zhang
Marco A Biamonte
Kevin D Hong
Jiandong Shi
Jean-Yves Le Brazidec
David Hurst
Marcus F Boehm
Original Assignee
Conforma Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conforma Therapeutics Corp filed Critical Conforma Therapeutics Corp
Publication of NO20061396L publication Critical patent/NO20061396L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
NO20061396A 2003-09-18 2006-03-27 Nye heterocykliske forbindelser som HSP90-inhibitorer NO20061396L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50413503P 2003-09-18 2003-09-18
US59146704P 2004-07-26 2004-07-26
PCT/US2004/031248 WO2005028434A2 (en) 2003-09-18 2004-09-20 Novel heterocyclic compounds as hsp90-inhibitors

Publications (1)

Publication Number Publication Date
NO20061396L true NO20061396L (no) 2006-06-16

Family

ID=34381103

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061396A NO20061396L (no) 2003-09-18 2006-03-27 Nye heterocykliske forbindelser som HSP90-inhibitorer

Country Status (14)

Country Link
US (8) US7138401B2 (US07138402-20061121-C00139.png)
EP (2) EP2145888A1 (US07138402-20061121-C00139.png)
JP (1) JP2007505933A (US07138402-20061121-C00139.png)
KR (1) KR20060070572A (US07138402-20061121-C00139.png)
CN (1) CN101906106A (US07138402-20061121-C00139.png)
AU (2) AU2004274507B2 (US07138402-20061121-C00139.png)
BR (1) BRPI0414533A (US07138402-20061121-C00139.png)
CA (1) CA2539548A1 (US07138402-20061121-C00139.png)
EA (1) EA010160B1 (US07138402-20061121-C00139.png)
IL (1) IL174375A0 (US07138402-20061121-C00139.png)
MX (1) MXPA06002997A (US07138402-20061121-C00139.png)
NO (1) NO20061396L (US07138402-20061121-C00139.png)
NZ (1) NZ546611A (US07138402-20061121-C00139.png)
WO (1) WO2005028434A2 (US07138402-20061121-C00139.png)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6992188B1 (en) * 1995-12-08 2006-01-31 Pfizer, Inc. Substituted heterocyclic derivatives
CN1501928A (zh) * 2000-11-02 2004-06-02 斯隆-凯特林癌症研究所 结合hsp90的小分子组合物
AU2002315389A1 (en) * 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
CA2464031A1 (en) 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
US7138401B2 (en) * 2003-09-18 2006-11-21 Conforma Therapeutics Corporation 2-aminopurine analogs having HSP90-inhibiting activity
WO2006050373A2 (en) * 2004-11-02 2006-05-11 The Regents Of The University Of California Methods and compositions for modulating apoptosis
RU2007120473A (ru) * 2004-11-02 2008-12-10 Конформа Терапьютикс Корпорейшн (Us) Способы лечения формы хронического лимфоцитарного лейкоза
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
US8212012B2 (en) * 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
EA013522B1 (ru) * 2005-03-30 2010-06-30 Конформа Терапьютикс Корпорейшн Алкинилпирролопиримидины и их применение в качестве ингибиторов hsp90
PL1877379T3 (pl) * 2005-04-13 2013-06-28 Astex Therapeutics Ltd Pochodne hydroksybenzamidu i ich wykorzystanie, jako inhibitorów hsp90
US20070027150A1 (en) * 2005-04-14 2007-02-01 Bellamacina Cornelia R 2-Amino-quinazolin-5-ones
WO2006124897A2 (en) * 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Methods and compositions for improving cognition
AU2006272876A1 (en) * 2005-07-22 2007-02-01 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
ES2577514T3 (es) * 2005-08-22 2016-07-15 The Regents Of The University Of California Antagonistas de TLR
CA2619365A1 (en) 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
CA2619972A1 (en) * 2005-08-24 2007-03-01 Lexicon Pharmaceuticals, Inc. Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use
EP1937258A2 (en) * 2005-09-23 2008-07-02 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
US20080269131A1 (en) * 2005-11-10 2008-10-30 Smithkline Beecham Corporation Inhibitors of Akt Activity
US20090227616A1 (en) * 2005-11-10 2009-09-10 Smithkline Beecham Corporation, A Corporation Inhibitors of akt activity
CA2634723A1 (en) * 2005-12-22 2007-07-05 Conforma Therapeutics Corporation Orally active purine-based inhibitors of heat shock protein 90
WO2007092496A2 (en) * 2006-02-07 2007-08-16 Conforma Therapeutics Corporation 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors
WO2007097839A2 (en) * 2006-02-16 2007-08-30 Massachusetts Eye And Ear Infirmary Ansamycin analogs or heat shock 90 inhibitors in combination with pdt treatin conditions of the eye
EP2038041A4 (en) * 2006-05-12 2010-02-17 Myriad Genetics Inc THERAPEUTIC COMPOUNDS AND THEIR USE AGAINST CANCER
EP2700638A1 (en) * 2006-05-31 2014-02-26 The Regents Of the University of California Purine analogs
EP2034839B1 (en) 2006-06-30 2017-08-23 Sloan-Kettering Institute for Cancer Research Treatment of neurodegenerative diseases through inhibition of hsp90
US20080009508A1 (en) * 2006-07-10 2008-01-10 Lucie Szucova 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin
DK1887359T3 (da) * 2006-08-03 2009-03-02 Cellzome Ag Fremgangsmåde til identifikation af PI3K-interagerende molekyler og til rensning af PI3K
ES2373160T3 (es) 2006-09-19 2012-02-01 Daiichi Sankyo Company, Limited Derivado de pirazolopirimidina.
WO2008045529A1 (en) * 2006-10-12 2008-04-17 Serenex, Inc. Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
FR2907453B1 (fr) * 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
GB0622084D0 (en) * 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
EP2108019A2 (en) * 2007-01-30 2009-10-14 Biogen Idec MA, Inc. 1-h-pyrazolo[3,4b]pyrimidine derivatives and their use as modulators of mitotic kinases
CA2675677A1 (en) * 2007-02-01 2008-08-07 Astrazeneca Ab 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
WO2008115319A2 (en) 2007-02-07 2008-09-25 Regents Of The University Of California Conjugates of synthetic tlr agonists and uses therefor
KR101313804B1 (ko) * 2007-03-20 2013-10-01 쿠리스 인코퍼레이션 Ｈｓｐ９０ 억제제로서의 융합된 아미노 피리딘
US8642554B2 (en) 2007-04-12 2014-02-04 Joyant Pharmaceuticals, Inc. Smac mimetic dimers and trimers useful as anti-cancer agents
US8143265B2 (en) * 2007-04-16 2012-03-27 Meharry Medical College Method of treating atherosclerosis
US7960353B2 (en) * 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
DE102007028521A1 (de) * 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
US8119616B2 (en) * 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2009036092A2 (en) 2007-09-10 2009-03-19 University Of Massachusetts Mitochondria-targeted anti-tumor agents
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US7960420B2 (en) 2007-12-21 2011-06-14 Joyant Pharmaceuticals, Inc Diazonamide analogs with improved solubility
US8895701B2 (en) * 2008-01-05 2014-11-25 Sloan-Kettering Institute For Cancer Research Peptide-conjugated oligonucleotide therapeutic and method of making and using same
EA201001264A1 (ru) * 2008-02-07 2011-04-29 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
US8190543B2 (en) * 2008-03-08 2012-05-29 Tokyo Electron Limited Autonomous biologically based learning tool
WO2009114470A2 (en) * 2008-03-10 2009-09-17 Curis, Inc. Tetrahydroindole and tetrahdyroindazole as hsp90 inhibitors containing a zinc binding moiety
WO2009114874A2 (en) * 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
JP5123429B2 (ja) 2008-04-29 2013-01-23 ジョイアント ファーマスーティカルズ、インク． インドリン抗癌剤
LT5623B (lt) 2008-04-30 2010-01-25 Biotechnologijos Institutas, , 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti
CN102098918A (zh) * 2008-05-13 2011-06-15 帕纳德制药公司 用于治疗癌症和神经退行性疾病的生物活性化合物
WO2009143485A1 (en) 2008-05-22 2009-11-26 Joyant Pharmaceuticals, Inc. Diazonamide analogs
CA2730106A1 (en) 2008-07-08 2010-01-14 Intellikine, Inc. Kinase inhibitors and methods of use
US20100022635A1 (en) * 2008-07-28 2010-01-28 University Of Kansas Heat shock protein 90 inhibitor dosing methods
GB0819102D0 (en) * 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
JP5501369B2 (ja) * 2008-11-25 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション 可溶性グアニレートシクラーゼ活性化剤
WO2010083403A1 (en) * 2009-01-16 2010-07-22 Curis, Inc. Fused amino pyridines for the treatment of brain tumors
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US8729088B2 (en) * 2009-02-11 2014-05-20 The Regents Of The University Of California Toll-like receptor modulators and treatment of diseases
RU2520966C2 (ru) 2009-02-25 2014-06-27 Дайити Санкио Компани, Лимитед Производное трициклического пиразолопиримидина
EP2414844B1 (en) * 2009-03-30 2014-12-10 Nordic Bioscience A/S Fibrosis biomarker assay
TW201102391A (en) * 2009-03-31 2011-01-16 Biogen Idec Inc Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
SG177384A1 (en) 2009-06-29 2012-02-28 Incyte Corp Pyrimidinones as pi3k inhibitors
EP2452940B1 (en) * 2009-07-10 2014-12-17 Taiho Pharmaceutical Co., Ltd. Azabicyclo compound and salt thereof
WO2011022439A1 (en) 2009-08-17 2011-02-24 Intellikine, Inc. Heterocyclic compounds and uses thereof
WO2011041593A1 (en) * 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
JP5941407B2 (ja) 2009-10-07 2016-06-29 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害剤
US8551955B2 (en) 2009-10-28 2013-10-08 Joyant Pharmaceuticals, Inc. Dimeric Smac mimetics
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
TW201130842A (en) * 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
JP2013514970A (ja) 2009-12-21 2013-05-02 バイエル・クロップサイエンス・アーゲー チエニルピリ（ミ）ジニルアゾール及び植物病原性菌類を防除するためのそれらの使用
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
US9173935B2 (en) 2010-04-30 2015-11-03 Telormedix Sa Phospholipid drug analogs
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
US9290499B2 (en) 2010-05-19 2016-03-22 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
EP2610259A4 (en) 2010-08-23 2014-01-08 Daiichi Sankyo Co Ltd TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE IN FREE CRYSTALLINE FORM
EP2610260A4 (en) 2010-08-23 2014-01-15 Daiichi Sankyo Co Ltd TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE IN CRYSTALLINE FORM
WO2012064744A2 (en) 2010-11-08 2012-05-18 Lycera Corporation Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease
CN103313989B (zh) 2010-12-16 2016-05-04 霍夫曼-拉罗奇有限公司 三环pi3k抑制剂化合物和使用方法
WO2012083181A1 (en) * 2010-12-16 2012-06-21 Indiana University Research And Technology Corporation Alpha helix mimetics and methods for using
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
CA2825028A1 (en) * 2011-02-09 2012-08-16 F. Hoffman-La Roche Ag Heterocyclic compounds as pi3 kinase inhibitors
CA2828483A1 (en) 2011-02-23 2012-11-01 Intellikine, Llc Combination of kinase inhibitors and uses thereof
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
CA2832099C (en) 2011-04-05 2019-07-09 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
KR102010222B1 (ko) 2011-04-05 2019-08-13 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 억제제
EP2699580B1 (en) 2011-04-22 2017-09-27 Joyant Pharmaceuticals, Inc. Diazonamide analogs
EP2714688B1 (en) 2011-05-26 2016-02-24 Daiichi Sankyo Company, Limited Heterocyclic compounds as protein kinase inhibitors
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
ITTO20110652A1 (it) * 2011-07-20 2013-01-21 Medestea Res & Production S P A Composto derivato dall'adenina avente azione immuno-modulante, antinfiammatoria e antidolorifica
MX2020004502A (es) 2011-09-02 2022-01-20 Incyte Holdings Corp Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k).
US9273056B2 (en) 2011-10-03 2016-03-01 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2847198B1 (en) 2012-05-08 2016-12-14 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ror-gamma and the treatment of disease
KR20150007300A (ko) 2012-05-08 2015-01-20 머크 샤프 앤드 돔 코포레이션 Ror감마 활성의 억제를 위한 테트라히드로나프티리딘 및 관련 비시클릭 화합물 및 질환의 치료
CA2912048A1 (en) * 2012-05-15 2013-11-21 Calasia Pharmaceuticals, Inc. Pyrimidine diamine derivatives as inhibitors of cytosolic hsp90
CA2873878A1 (en) 2012-05-22 2013-11-28 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
EP3795694A3 (en) 2012-10-02 2021-06-23 The General Hospital Corporation d/b/a Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
EP2912036A1 (en) 2012-10-04 2015-09-02 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
CN103724269B (zh) * 2012-10-11 2016-12-21 中国科学院上海药物研究所 苯基1,2-异噁唑或苯基1,2-吡唑类化合物及其用途
WO2014062774A1 (en) 2012-10-17 2014-04-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
WO2014085225A1 (en) 2012-11-27 2014-06-05 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
NZ731337A (en) 2012-12-07 2019-02-22 Vertex Pharma Compounds useful as inhibitors of atr kinase
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
WO2014143242A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2016512239A (ja) 2013-03-15 2016-04-25 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
WO2014145576A2 (en) * 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
JP6360881B2 (ja) 2013-03-22 2018-07-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 触媒的ｍｔｏｒｃ１／２阻害薬及びオーロラａキナーゼの選択的阻害薬の組合せ
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
AU2014293011A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene
AU2014306417C1 (en) 2013-08-16 2019-07-25 Memorial Sloan-Kettering Cancer Center Selective Grp94 inhibitors and uses thereof
PL3077397T3 (pl) 2013-12-06 2020-04-30 Vertex Pharmaceuticals Inc. Związek 2-amino-6-fluoro-n-[5-fluoro-pirydyn-3-ylo]pyrazolo [1,5-a]pirymidino-3-karboksamidu przydatny jako inhibitor kinazy atr, jego wytwarzanie, różne postacie stałe i ich radioznakowane pochodne
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
WO2015095792A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
WO2015095795A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
US10532088B2 (en) 2014-02-27 2020-01-14 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
ES2548927B1 (es) * 2014-03-21 2016-08-11 Universidad De Granada Derivados de purina como inhibidores de Dapk-1
CN106459063A (zh) * 2014-04-11 2017-02-22 北卡罗来纳-查佩尔山大学 Mertk‑特异性嘧啶化合物
EP3209641A4 (en) 2014-05-05 2018-06-06 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease
CA2947290A1 (en) 2014-05-05 2015-11-12 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
SI3152212T1 (sl) 2014-06-05 2020-06-30 Vertex Pharmaceuticals Inc. Radioaktivno označeni derivati 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)-pirazolo (1,5-A)pirimidin-3- karboksamidne spojine, koristni kot inhibitor kinaze ATR, priprava navedene spojine in njene različne trdne oblike
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
RS59054B1 (sr) 2014-06-17 2019-08-30 Vertex Pharma Postupak za lečenje raka korišćenjem kombinacije chk1 i atr inhibitora
MA40535A (fr) 2014-09-17 2016-03-24 Memorial Sloan Kettering Cancer Center Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
KR101713638B1 (ko) * 2014-11-18 2017-03-08 한국과학기술연구원 신규한 피롤로 피리미딘 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
CA2975997A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134320A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
NZ734993A (en) 2015-02-27 2024-03-22 Incyte Holdings Corp Salts of pi3k inhibitor and processes for their preparation
CA2982847A1 (en) 2015-05-05 2016-11-10 Lycera Corporation Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
KR20180025894A (ko) 2015-06-11 2018-03-09 라이세라 코퍼레이션 Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료
MA42023B2 (fr) * 2015-07-20 2022-01-31 Genzyme Corp Inhibiteurs du récepteur de facteur-1 de stimulation de colonies (csf-1r)
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
CA3002853A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
CN108431009A (zh) 2015-10-27 2018-08-21 默沙东公司 作为RORγT抑制剂的取代的吲唑化合物及其用途
WO2017075178A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
KR101896616B1 (ko) * 2016-10-11 2018-09-07 한국과학기술연구원 2-아미노 퓨린 유도체 화합물, 이를 제조하는 방법, 및 이의 용도
KR102053933B1 (ko) * 2016-10-26 2019-12-11 울산과학기술원 Trap1 저해제로서 유용한 화합물 및 이를 포함하는 항암용 조성물
LT3448859T (lt) 2017-03-20 2019-10-25 Forma Therapeutics Inc Pirolpirolo kompozicijos, kaip piruvato kinazės (pkr) aktyvatoriai
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US10472361B2 (en) * 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
CN107857763A (zh) * 2017-11-28 2018-03-30 江苏杏睿生物科技有限公司 一种邻硝基芳酰化衍生物类化合物、制备方法及其应用
FR3075795A1 (fr) 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
FR3075794A1 (fr) * 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
BR112020018286A2 (pt) 2018-03-09 2020-12-29 Recurium Ip Holdings, Llc 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas
MA52494A (fr) 2018-05-04 2021-03-10 Incyte Corp Formes solides d'un inhibiteur de fgfr et leurs procédés de préparation
EP3788046A1 (en) 2018-05-04 2021-03-10 Incyte Corporation Salts of an fgfr inhibitor
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
US11001588B2 (en) 2018-09-19 2021-05-11 Forma Therapeutics, Inc. Activating pyruvate kinase R and mutants thereof
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4045151A1 (en) 2019-10-14 2022-08-24 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR102516260B1 (ko) * 2020-07-10 2023-03-31 울산과학기술원 Trap1 선택적 억제제로서의 화합물 및 이를 포함하는 암 예방 또는 치료용 조성물
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
CN116332940A (zh) * 2023-02-14 2023-06-27 广西民族大学 一种7-脱氮嘌呤衍生物及其制备方法和应用

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB884151A (en) 1957-12-06 1961-12-06 Ciba Ltd New pyrazolo-pyrimidines substituted in the pyrazole nucleus, and process for their manufacture
IL64501A (en) 1980-12-22 1985-07-31 Astra Laekemedel Ab 9-substituted 4-hydroxybutyl guanine derivatives,their preparation and antiviral use
US4699877A (en) 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US5098906A (en) 1983-10-31 1992-03-24 Warner-Lambert Company Purine derivatives
US4806642A (en) 1984-10-05 1989-02-21 Warner-Lambert Company Purine derivatives
US4921859A (en) * 1983-10-31 1990-05-01 Warner-Lambert Company Purine derivatives
US4547573A (en) 1983-12-02 1985-10-15 Ici Pharma Process for preparing cephalosporin derivatives
EP0151528B1 (en) 1984-02-02 1990-07-04 Merck & Co. Inc. 5-(amino or substituted amino)-1,2,3-triazoles
US4748177A (en) 1984-03-26 1988-05-31 Warner-Lambert Company Guanine derivatives
US4617304A (en) * 1984-04-10 1986-10-14 Merck & Co., Inc. Purine derivatives
IT1196261B (it) * 1984-09-20 1988-11-16 Pierrel Spa Derivati nucleosidici e purinici 8-sostituiti
US4772606A (en) 1985-08-22 1988-09-20 Warner-Lambert Company Purine derivatives
ZA857647B (en) * 1984-10-12 1986-05-28 Warner Lambert Co Purine derivatives
IL76546A (en) 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
JO1406B1 (en) 1984-11-02 1986-11-30 سميث كلاين اند فرينش لابوراتوريز ليمتد Chemical compounds
ATE81872T1 (de) 1985-03-15 1992-11-15 James Summerton Stereoregulare polynukleotiden bindende polymere.
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
IL78643A0 (en) 1985-05-02 1986-08-31 Wellcome Found Purine derivatives,their preparation and pharmaceutical compositions containing them
GB8515934D0 (en) 1985-06-24 1985-07-24 Janssen Pharmaceutica Nv (4-piperidinomethyl and-hetero)purines
US4918162A (en) 1986-05-06 1990-04-17 The Regents Of The University Of California Assays and antibodies for N-MYC proteins
DE3623099C3 (de) * 1986-07-09 1998-08-13 Spoetzl Markus Dipl Ing Fh Blasformmaschine
US5002950A (en) * 1986-10-24 1991-03-26 Warner-Lambert Co. 7-deazaguanines as immunomodulators
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5204353A (en) 1987-04-07 1993-04-20 Ciba-Geigy Corporation 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith
JPH0821101B2 (ja) 1987-07-21 1996-03-04 三洋電機株式会社 硬貨選別装置
SE8801729D0 (sv) 1988-05-06 1988-05-06 Astra Ab Purine derivatives for use in therapy
US4923885A (en) 1988-08-19 1990-05-08 Merck & Co., Inc. 5-amino-1-(4-naphthoylbenzyl)-1,2,3-triazole-4-carboxamides and analogs as antiproliferative agents
EP0363320A3 (de) 1988-10-06 1991-11-21 Ciba-Geigy Ag Substituierte 9H-Purine
US5332744A (en) 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
ES2085446T3 (es) 1990-07-04 1996-06-01 Merrell Pharma Inc Derivados de acido 9-purinil fosfonico.
GB9020931D0 (en) 1990-09-26 1990-11-07 Wellcome Found Heterocyclic compounds
ATE187173T1 (de) 1991-03-05 1999-12-15 Ajinomoto Kk Cyclopropanderivat
US5939420A (en) 1991-04-08 1999-08-17 Duquesne University Of The Holy Ghost Pyrrolo 2,3d!derivatives
WO1992021032A1 (en) * 1991-05-24 1992-11-26 The Regents Of The University Of California Methods for the detection of bcr-abl and abnormal abl proteins in leukemia patients
US6025126A (en) * 1991-10-28 2000-02-15 Arch Development Corporation Methods and compositions for the detection of chromosomal aberrations
CA2093403C (en) 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
JPH0680670A (ja) 1992-09-03 1994-03-22 Ajinomoto Co Inc シクロプロパン誘導体及びその製造法
GB9226879D0 (en) 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
US6005107A (en) 1992-12-23 1999-12-21 Biochem Pharma, Inc. Antiviral compounds
US6444656B1 (en) * 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
US5744492A (en) 1993-09-17 1998-04-28 United States Of America Method for inhibiting angiogenesis
US5602156A (en) 1993-09-17 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Method for inhibiting metalloproteinase expression
GB9402161D0 (en) * 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
JP3769737B2 (ja) 1994-03-30 2006-04-26 味の素株式会社 シクロプロパン誘導体及びその製造法
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US6110923A (en) 1994-06-22 2000-08-29 Biochem Pharma Inc. Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH0841035A (ja) 1994-08-05 1996-02-13 Ajinomoto Co Inc シクロプロパン誘導体及びその製造法
US5846749A (en) 1994-10-12 1998-12-08 The Regents Of The University Of California Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
JPH08208687A (ja) 1994-11-25 1996-08-13 Sankyo Co Ltd グリセリルオリゴヌクレオチド
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US6177460B1 (en) * 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
JPH0920776A (ja) 1995-06-30 1997-01-21 Nippon Paper Ind Co Ltd 新規なプリンヌクレオシド誘導体、その製造方法及びその誘導体を有効成分とする抗ウイルス剤
JPH09169758A (ja) 1995-10-18 1997-06-30 Nippon Paper Ind Co Ltd 新規なプリンヌクレオシド誘導体、その製造方法、及びそれを用いた抗ウイルス剤
JPH1025294A (ja) 1996-03-26 1998-01-27 Akira Matsuda 縮合ヘテロ環誘導体、その製造法及びそれを含有する悪性腫瘍治療剤
ATE283855T1 (de) 1996-07-03 2004-12-15 Sumitomo Pharma Neue purinderivate
US6723727B1 (en) 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
US6284748B1 (en) 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
US5861503A (en) 1997-04-30 1999-01-19 The Regents Of The University Of California Process for producing 8-fluoropurines
ATE460423T1 (de) 1997-05-14 2010-03-15 Sloan Kettering Inst Cancer Verfahren und zubereitungen zur zerstörung bestimmter proteine
NZ502642A (en) 1997-07-03 2002-06-28 Du Pont Pharm Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
CA2294244A1 (en) 1997-07-12 1999-01-21 Cancer Research Campaign Technology Limited Cyclin dependent kinase inhibiting purine derivatives
GB9717849D0 (en) 1997-08-23 1997-10-29 Seal Sands Chemicals Limited Preparation of pyridene derivatives
AUPO912997A0 (en) 1997-09-11 1997-10-02 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
KR100540046B1 (ko) 1997-11-12 2006-01-10 미쓰비시 가가꾸 가부시키가이샤 퓨린유도체 및 이를 유효성분으로 함유하는 의약
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
AU3378599A (en) 1998-04-03 1999-10-25 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
US5985060A (en) 1998-07-25 1999-11-16 Breed Automotive Technology, Inc. Gas generant compositions containing guanidines
SI20022A (sl) 1998-07-29 2000-02-29 Kemijski inštitut Alkilno substituirani purinovi derivati in njihova priprava
JP2000072773A (ja) 1998-08-28 2000-03-07 Zeria Pharmaceut Co Ltd プリン誘導体
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
DE60042731D1 (de) * 1999-01-06 2009-09-24 Univ Southern California Methode und zubereitung zur hemmung von angiogenese
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
WO2000044750A1 (en) 1999-02-01 2000-08-03 Cv Therapeutics, Inc. PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND Iλ-A$g(a)
FR2790702B1 (fr) 1999-03-08 2001-07-20 Sidel Sa Unite de moulage et machine d'extrusion-soufflage munie d'une telle unite
US6174875B1 (en) 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
WO2000068230A1 (en) 1999-05-05 2000-11-16 Darwin Discovery Limited 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7 inhibitors
US6660845B1 (en) * 1999-11-23 2003-12-09 Epoch Biosciences, Inc. Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
EP1244672B1 (en) 1999-12-21 2005-07-20 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
JP2003519232A (ja) 2000-01-07 2003-06-17 ウニフェルジテーレ・インステリング・アントウェルペン プリン誘導体、その製造法およびその使用
EP1265913A4 (en) 2000-03-24 2004-07-14 Univ Duke CHARACTERIZATION OF LIGANDS-GRP94 INTERACTIONS AND RELATED PURIFICATION, SCREENING AND PROCESSING METHODS
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
AU5566701A (en) 2000-04-25 2001-11-07 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
AU2001271567A1 (en) 2000-06-29 2002-01-14 Trustees Of Boston University Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
US6946456B2 (en) 2000-07-28 2005-09-20 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
US6613089B1 (en) 2000-10-25 2003-09-02 Sdgi Holdings, Inc. Laterally expanding intervertebral fusion device
CN1501928A (zh) 2000-11-02 2004-06-02 斯隆-凯特林癌症研究所 结合hsp90的小分子组合物
CN1473055A (zh) 2000-11-02 2004-02-04 ˹¡-�����ְ�֢�о��� 通过使用hsp90抑制剂提高细胞毒剂效力的方法
GB0100621D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
GB0100623D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
MY141789A (en) 2001-01-19 2010-06-30 Lg Chem Investment Ltd Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.
AU2002252179A1 (en) 2001-03-01 2002-09-19 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
CA2377054C (en) * 2001-03-16 2006-09-05 Susan M. Boyetchko Biocontrol of weeds using pseudomonas compositions
JP4331944B2 (ja) 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
US20020156277A1 (en) 2001-04-20 2002-10-24 Fick David B. Synthesis and methods of use of purine analogues and derivatives
US20030022864A1 (en) 2001-04-24 2003-01-30 Ishaq Khalid S. 9-[(5-dihydroxyboryl)-pentyl] purines, useful as an inhibitor of inflammatory cytokines
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2002094196A2 (en) 2001-05-23 2002-11-28 Sloan Kettering Institute For Cancer Research Method of treatment for cancers associated with elevated
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
US6949522B2 (en) 2001-06-22 2005-09-27 Pharmasset, Inc. β-2′- or 3′-halonucleosides
DE60205376T2 (de) 2001-06-27 2006-04-06 Cyclacel Ltd. 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
US6962991B2 (en) 2001-09-12 2005-11-08 Epoch Biosciences, Inc. Process for the synthesis of pyrazolopyrimidines
DK1499277T3 (da) 2001-09-24 2009-05-11 Imp Innovations Ltd PYY-36 til reduktion eller forebyggelse af obesitet
ATE387198T1 (de) 2001-09-24 2008-03-15 Conforma Therapeutic Corp Verfahren zur herstellung von 17-allyl-amino- geldanamycin (17-aag) und anderer ansamycine
JP2003113181A (ja) 2001-10-04 2003-04-18 Sumika Fine Chemicals Co Ltd ６−ハロプリンの製造方法
CA2464031A1 (en) * 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
WO2003041643A2 (en) 2001-11-09 2003-05-22 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
WO2004024082A2 (en) * 2002-09-13 2004-03-25 Irm, Llc Highly specific modulators of gtpases for target validation
US7601694B2 (en) * 2003-02-20 2009-10-13 New York University CLK-peptide and SLK-peptide
JP2007526894A (ja) * 2003-07-16 2007-09-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グリコーゲンシンターゼキナーゼ３インヒビターとしてのトリアゾロピリミジン誘導体
JP2009514782A (ja) * 2003-07-16 2009-04-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グリコーゲン合成酵素キナーゼ３阻害剤としてのトリアゾロピリミジン誘導体
WO2005016348A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
US7138401B2 (en) 2003-09-18 2006-11-21 Conforma Therapeutics Corporation 2-aminopurine analogs having HSP90-inhibiting activity
US20080081817A1 (en) * 2004-07-23 2008-04-03 Tanabe Seiyaku Co., Ltd. Nitrogenous Fused Bicyclic Compound
EP1937258A2 (en) * 2005-09-23 2008-07-02 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
TWI640539B (zh) 2015-03-13 2018-11-11 朱寶麒 鋅結合之麩胺基硫轉移酶與金屬硫蛋白融合蛋白

Also Published As

Publication number Publication date
US20050113340A1 (en) 2005-05-26
CN101906106A (zh) 2010-12-08
AU2010202750B2 (en) 2011-09-01
EA200600594A1 (ru) 2006-10-27
BRPI0414533A (pt) 2006-11-07
AU2004274507A1 (en) 2005-03-31
AU2010202750A1 (en) 2010-07-22
US20070173483A1 (en) 2007-07-26
US7148228B2 (en) 2006-12-12
MXPA06002997A (es) 2007-02-08
US7138402B2 (en) 2006-11-21
US7138401B2 (en) 2006-11-21
EP1670802A4 (en) 2010-07-07
CA2539548A1 (en) 2005-03-31
US20070111997A1 (en) 2007-05-17
EP1670802A2 (en) 2006-06-21
WO2005028434A2 (en) 2005-03-31
US20050119282A1 (en) 2005-06-02
US20070185064A1 (en) 2007-08-09
US20050107343A1 (en) 2005-05-19
NZ546611A (en) 2010-02-26
WO2005028434A3 (en) 2006-03-23
US7129244B2 (en) 2006-10-31
US20050113339A1 (en) 2005-05-26
IL174375A0 (en) 2006-08-01
AU2004274507B2 (en) 2010-08-19
JP2007505933A (ja) 2007-03-15
EA010160B1 (ru) 2008-06-30
EP2145888A1 (en) 2010-01-20
US20070111996A1 (en) 2007-05-17
KR20060070572A (ko) 2006-06-23

Similar Documents

Publication Publication Date Title
NO20061396L (no) Nye heterocykliske forbindelser som HSP90-inhibitorer
ATE495162T1 (de) Azabicyclo-octan und nonan derivate mit ddp-iv hemmender wirkung
NO20052546D0 (no) Substituert arylthiourea og relaterte forbindelser; inhibitorer av viral reproduksjon.
NO20071320L (no) Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer.
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
IS7258A (is) Arýloxýfenýl og arýlsúlfanýlfenýl afleiður
CY1109006T1 (el) Παραγωγα πουρινης ως αναστολεις κινασης
NO20050828L (no) lndol-3-svovelderivater
NO20082482L (no) Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer
NO20005237L (no) Heterocyklisk substituerte amider anvendt som calpain- inhibitorer
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
DE602004006433D1 (de) Pyrrol-substituierte indole als inhibitoren von pai-1
NO20071619L (no) Fremgangsmate for fremstilling av indazol forbindelse
NO20061789L (no) Aminopyridinderivater som induserbare NO-syntaseinhibitorer
NO20043842L (no) Nye krystallformer av atorvastatinhemikalsium og fremgangsmater for fremstilling derav, savel som nye fremgangsmater for fremstilling av atorvastatinhemikalsiumform I, VIII og IX
CY1106471T1 (el) Νεα μεθοδος συνθεσης της περινδροπριλης και των φαρμακευτικως αποδεκτων αλατων αυτης
NO20051844L (no) Piperazinderivater og fremgangsmate for anvendelse derav.
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
DE60316984D1 (de) Benzoylsulfonamide als antitumor-mittel
NO20052994L (no) Nye fosforamidderivater.
DE60112742D1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
DE602004005016D1 (de) Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
EA200501925A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application